CAR T-cell Therapy Cilta-cel Continues to Show Benefits in Heavily Treated Myeloma Patients
Ciltacabtagene autoleucel, an investigational CAR T-cell therapy for multiple…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma
The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana…
Roche’s Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients
Cevostamab (BFCR4350A), a bispecific antibody developed by…
Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets
Antengene is asking health authorities in Singapore, Australia, and…
Dana-Farber, Quest Diagnostics Studying COVID-19 Prevalence in Myeloma
The Dana-Farber Cancer Institute and Quest Diagnostics,…
FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A
The U.S. Food and Drug Administration (FDA) has lifted…
